News Snapshot:
LOS ANGELES, May 23 (Xinhua) -- Pfizer and its German partner BioNTech said Monday that preliminary clinical data showed their three-dose COVID-19 vaccine regimen was 80 percent effective for children 6 months to 5 years old at preventing illness during the Omicron wave. The vaccine was found to elicit a strong immune response following a third dose, and was well tolerated by the kids with a majority of the side effects mild to moderate, according to the companies. The safety data for the Pfizer vaccine is based on 1,678 children under age 5 who received a third shot at least...
